These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 30006773)
21. Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Pinazo MJ; Guerrero L; Posada E; Rodríguez E; Soy D; Gascon J Antimicrob Agents Chemother; 2013 Jan; 57(1):390-5. PubMed ID: 23114763 [TBL] [Abstract][Full Text] [Related]
22. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. Pérez-Molina JA; Pérez-Ayala A; Moreno S; Fernández-González MC; Zamora J; López-Velez R J Antimicrob Chemother; 2009 Dec; 64(6):1139-47. PubMed ID: 19819909 [TBL] [Abstract][Full Text] [Related]
23. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil. Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500 [TBL] [Abstract][Full Text] [Related]
25. Adverse systemic reaction to benznidazole. Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820 [TBL] [Abstract][Full Text] [Related]
26. Current and developing therapeutic agents in the treatment of Chagas disease. Apt W Drug Des Devel Ther; 2010 Sep; 4():243-53. PubMed ID: 20957215 [TBL] [Abstract][Full Text] [Related]
27. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole. Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135 [TBL] [Abstract][Full Text] [Related]
28. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. de Andrade AL; Zicker F; de Oliveira RM; Almeida Silva S; Luquetti A; Travassos LR; Almeida IC; de Andrade SS; de Andrade JG; Martelli CM Lancet; 1996 Nov; 348(9039):1407-13. PubMed ID: 8937280 [TBL] [Abstract][Full Text] [Related]
30. Treatment with benznidazole in association with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi: investigation into the possible development of neoplasias. Andrade SG; Mesquita IM; Jambeiro JF; Santos IF; Portella RS Rev Soc Bras Med Trop; 2003; 36(4):441-7. PubMed ID: 12937719 [TBL] [Abstract][Full Text] [Related]
32. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113 [TBL] [Abstract][Full Text] [Related]
33. [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation]. Coura JR; de Abreu LL; Willcox HP; Petana W Rev Soc Bras Med Trop; 1997; 30(2):139-44. PubMed ID: 9148337 [TBL] [Abstract][Full Text] [Related]
34. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Torrico F; Gascón J; Barreira F; Blum B; Almeida IC; Alonso-Vega C; Barboza T; Bilbe G; Correia E; Garcia W; Ortiz L; Parrado R; Ramirez JC; Ribeiro I; Strub-Wourgaft N; Vaillant M; Sosa-Estani S; Lancet Infect Dis; 2021 Aug; 21(8):1129-1140. PubMed ID: 33836161 [TBL] [Abstract][Full Text] [Related]
35. Adverse events after the use of benznidazole in infants and children with Chagas disease. Altcheh J; Moscatelli G; Moroni S; Garcia-Bournissen F; Freilij H Pediatrics; 2011 Jan; 127(1):e212-8. PubMed ID: 21173000 [TBL] [Abstract][Full Text] [Related]
37. Benznidazole for the treatment of Chagas disease. Losada Galván I; Alonso-Padilla J; Cortés-Serra N; Alonso-Vega C; Gascón J; Pinazo MJ Expert Rev Anti Infect Ther; 2021 May; 19(5):547-556. PubMed ID: 33043726 [TBL] [Abstract][Full Text] [Related]
38. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina. Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950 [TBL] [Abstract][Full Text] [Related]
39. An update on benznidazole for the treatment of patients with Chagas disease. Thakare R; Dasgupta A; Chopra S Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658 [TBL] [Abstract][Full Text] [Related]
40. [Treatment of Chagas disease with benznidazole and thioctic acid]. Roldán EJ Medicina (B Aires); 2005; 65(1):85-6; author reply 86-7. PubMed ID: 15830800 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]